GSK 2636771

Drug Profile

GSK 2636771

Alternative Names: GSK2636771

Latest Information Update: 05 May 2016

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Antineoplastics; Benzimidazoles
  • Mechanism of Action Phosphatidylinositol 3 kinase beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours
  • Phase I Prostate cancer

Most Recent Events

  • 01 Apr 2016 GlaxoSmithKine completes a phase-I/II trial for Solid tumours (Late-stage disease) in USA, United Kingdom and South Korea (NCT01458067)
  • 24 Nov 2015 Yonsei University plans a phase Ib/IIa trial for Gastric-cancer (Combination therapy, Late-stage disease) in South Korea (NCT02615730)
  • 01 Nov 2014 Phase-I clinical trials in Prostate cancer (Combination therapy, Late-stage disease, Metastatic disease) in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top